Upside Options Flow in Bristol-Myers

 
 
By David Russell of OptionMonster
 
NEW YORK -- Pharmaceuticals were strong on Friday, and upside options were really flowing in Bristol-Myers Squibb (BMY).
 
OptionMonster's tracking systems detected bullish activity at two strikes in particular. Traders started with the shorter-term Weekly 54 calls expiring on Dec. 6, snapping up more than 5,000 contracts in volume well above previous open interest of 1,316. Premiums rose from 22 cents to 41 cents, with most of the large blocks pricing for 24 cents to 34 cents. .
 
These long calls lock in the price where a stock can be purchased, letting investors profit from a rally while risking only small amounts of capital. Their cheap cost also offers the potential for significant leverage if the drug maker pushes higher.
 
About an hour later, buyers turned to the March 52.50 calls, mostly paying $2.92. Some 5,400 changed hands against open interest of 1,047 contracts.
 
Bristol-Myers ended the session up 2.02% to $53.41. The company received a key upgrade from Morgan Stanley on Oct. 28 based on the promise of its cancer treatments. Shares have been consolidating at their highest levels in more than a decade since then.
 
Total option volume in the name was four times greater than average in the session. Overall calls outnumbered puts by almost 5 to 1.
 
Russell has no positions in BMY.

This commentary comes from an independent investor or market observer as part of TheStreet guest contributor program. The views expressed are those of the author and do not necessarily represent the views of TheStreet or its management.

If you liked this article you might like

Bristol-Myers Squibb Stock Still a Beast?

There Are Good Opportunities in Stock Picking

Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers

Achillion Shares Are Plunging on Termination of Hepatitis C Pact